Skip to content

Two new formulations receive European go-ahead

Tipranavir superior to other PIs in detailed resistance analysis

Entecavir gains ground as anti-HBV option in HIV-coinfected patients

TMC114 appears to be strong PI option for salvage therapy

Investigational NNRTI TMC278 swiftly cuts viral load in treatment-naive patients

Two new drug classes given to people with HIV for the first time

Addition of capravirine to a three-drug regimen not beneficial in patients with NNRTI resistance

HIV co-receptor use in the blood and central nervous system differs in 20% of patients

Pegasys approved in Europe for treatment of HCV in HIV/HCV coinfected patients